LXR Protein (Liver X Receptor)
Overview <table class="infobox infobox-protein">
...
LXR Protein (Liver X Receptor)
Overview <table class="infobox infobox-protein">
Liver X receptors (LXRs) are nuclear receptors that function as master regulators of cholesterol homeostasis and lipid metabolism[@zelcer2005]. There are two LXR isoforms: LXRα (NR1H3) and LXRβ (NR1H2), which are ligand-activated transcription factors that sense oxysterols and regulate genes involved in cholesterol efflux, metabolism, inflammation, and brain function[@nagai2005]. LXRs have emerged as important therapeutic targets for neurodegenerative diseases due to their ability to modulate cholesterol metabolism, reduce neuroinflammation, and promote amyloid clearance in the brain[@wang2006].
Protein Structure LXR proteins have the typical nuclear receptor architecture:
Domain Architecture LXR Protein Structure
DBD: DNA-binding domain (zinc fingers)
N-terminal AF-1 Domain : Variable, confers isoform-specific transcriptional activationDNA-binding Domain (DBD) : Contains two C4-type zinc fingers that bind to DR-4 response elementsHinge Region : Flexible linker allowing conformational changesLigand-binding Domain (LBD) : Hydrophobic pocket binds oxysterols and synthetic agonistsAF-2 Region : Helix 12 that completes the agonist-bound conformationNormal Biological Function
LXRs are the body's primary cholesterol sensors:
Cholesterol Efflux Regulation :Activate ABCA1: Promotes [ApoE](/proteins/apoe) lipidation and cholesterol efflux to ApoA1
Activate ABCG1: Mediates cholesterol efflux to HDL
Activate ABCG4: Brain-specific cholesterol efflux
Cholesterol Transport :Regulate APOE expression in brain
Control CYP7A1 (cholesterol 7α-hydroxylase) in liver
Modulate LDL receptor expression
Anti-inflammatory Effects LXRs have profound anti-inflammatory properties:
Transrepression : Inhibit [NF-κB](/entities/nf-kb) transcription without DNA bindingCOX-2 Suppression : Reduce prostaglandin synthesisiNOS Inhibition : Decrease nitric oxide productionCytokine Regulation : Modulate IL-1β, TNF-α, IL-6 expressionFatty Acid Synthesis : Activate SREBP-1c for lipogenesisTriglyceride Regulation : Modulate lipogenic gene expressionPhospholipid Metabolism : Control lipid compositionRole in Neurodegeneration
Alzheimer's Disease LXRs are particularly important in AD pathogenesis:
Amyloid Pathology:
LXR agonists reduce amyloid-β deposition in mouse models[@van2019]
ABCA1/LXR pathway affects APOE lipidation and [Aβ](/proteins/amyloid-beta) clearance
Enhanced microglial cholesterol efflux reduces amyloid burden
Cognitive Function:
LXR activation improves memory in AD models
Synaptic protection through cholesterol regulation
Neuroinflammatory reduction
Therapeutic Implications:
LXR agonists (GW3965, T0901317) show promise in preclinical studies
Selective LXRβ agonists avoid peripheral side effects
ABCA1 activators as alternative approach
Parkinson's Disease LXR activation provides neuroprotection in PD:
Dopaminergic Neuron Protection:
Reduced oxidative stress in substantia nigra
Enhanced mitochondrial function
Anti-apoptotic effects
Neuroinflammation:
Suppression of microglial activation
Reduced dopaminergic neuron loss
Modulation of glial cell function
Potential Therapeutics:
LXR agonists protect against MPTP toxicity
GW3965 reduces neuroinflammation
Combined approach with L-DOPA
Amyotrophic Lateral Sclerosis
Modulation of lipid metabolism in motor [neurons](/entities/neurons)
Anti-inflammatory effects
Energy metabolism support
Frontotemporal Dementia
Cholesterol regulation in neurons
Neuroinflammatory pathways
Lipid droplet metabolism
Genetic Associations
Protein Interactions
Transcriptional Complexes
Signaling Cross-talk
PPAR Pathway : Cross-activation with PPARγSREBP Pathway : Coordinate lipid regulationNF-κB : Reciprocal repressionExpression Patterns in the Brain
Cellular Distribution
Neurons : High expression, particularly in [cortex](/brain-regions/cortex) and [hippocampus](/brain-regions/hippocampus)[Astrocytes](/entities/astrocytes) : Moderate to high expression[Microglia](/cell-types/microglia-neuroinflammation) : LXRβ predominant, increases with activationOligodendrocytes : Lower expressionRegulation
Ligand-dependent : Activated by oxysterolsCholesterol levels : Feedback regulationInflammatory signals : NF-κB suppresses LXR activityTherapeutic Implications
Synthetic LXR Agonists
GW3965 : Widely used research agonistGood brain penetration
Reduces amyloid pathology
Improves cognition
T0901317 : Potent LXR agonistStrong cholesterol efflux effect
Liver toxicity concerns
LXR-623 (Way-254011) : Selective LXRβReduced liver side effects
Clinical trials for atherosclerosis
Challenges and Solutions
Peripheral Side Effects : Selective LXRβ agonistsLipogenesis : Tissue-specific deliveryBrain Penetration : Optimized compoundsAlternative Approaches
ABCA1 Direct Activators : Avoid LXR side effectsGene Therapy : Target ABCA1 expressionAPOE Modulators : Enhance lipidation[Cholesterol Metabolism](/data/pages/cerebral_cholesterol_metabolism)
[APOE and Lipid Metabolism](/mechanisms/apoe-lipid-metabolism)
[NF-κB Signaling](/mechanisms/nf-kb-signaling-neuroinflammation)
[Microglial Activation](/mechanisms/microglia-neuroinflammation)
[Amyloid Clearance](/mechanisms/amyloid-clearance-pathways)
[NR1H3 Gene (LXRα)](/genes/nr1h3)
[NR1H2 Gene (LXRβ)](/genes/nr1h2)
[ABCA1 Protein](/proteins/abcg1-protein)
[APOE Protein](/proteins/apoe-protein)
[RXR Protein](/proteins/rxra-protein)
[TREM2 Protein](/proteins/trem2-protein)
Pathway & Interaction Diagram Interactive diagram showing LXR's key relationships in the SciDEX knowledge graph (9 connections shown).
Mermaid diagram (expand to render)
See Also
[APOE and Lipid Metabolism](/mechanisms/apoe-lipid-metabolism)
[NF-κB Signaling](/mechanisms/nf-kb-signaling-neuroinflammation)
[Microglial Activation](/mechanisms/microglia-neuroinflammation)
[Amyloid Clearance](/mechanisms/amyloid-clearance-pathways)
External Links
[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Zelcer et al., LXR functions in cholesterol homeostasis (2005) (2005)](https://pubmed.ncbi.nlm.nih.gov/15976172/)
[Nagai et al., LXR isoforms in brain (2005) (2005)](https://pubmed.ncbi.nlm.nih.gov/15944626/)
[Wang et al., LXR agonists in AD models (2006) (2006)](https://pubmed.ncbi.nlm.nih.gov/16400059/)
[Van der Kant et al., LXR and amyloid clearance (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30605878/)
[Galea et al., LXR in neuroinflammation (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/27013186/) Show full description